Reata Pharmaceuticals, Inc. to Report Second Quarter 2020 Financial Results and to Provide an Update on Development Programs on August 10, 2020
Reata Pharmaceuticals (Nasdaq: RETA) will release its financial results for Q2 2020 and provide updates on its development programs on August 10, 2020, before market hours. A conference call will follow at 8:30 a.m. ET, accessible via phone or webcast. Reata specializes in novel therapeutics targeting serious diseases, with key candidates bardoxolone methyl and omaveloxolone focusing on inflammation and mitochondrial function. These drugs are still in development, and their safety and efficacy remain unproven.
- Plans to announce Q2 2020 financial results on August 10, 2020.
- Conference call scheduled for August 10, 2020, at 8:30 a.m. ET.
- None.
PLANO, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on its development programs pre-market on August 10, 2020.
Reata’s management will host a conference call on August 10, 2020 at 8:30 a.m. ET. The conference call will be accessible by dialing (800) 708-4539 (toll-free domestic) or (847) 619-6396 (international) using the access code: 49873533. The webcast link is https://edge.media-server.com/mmc/p/hr8ew88f.
Second quarter 2020 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://reatapharma.com/investors/ and which will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at http://reatapharma.com/investors/.
About Reata Pharmaceuticals, Inc.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Contact:
Reata Pharmaceuticals, Inc.
(972) 865-2219
http://reatapharma.com
Investors:
Vinny Jindal
Vice President, Corporate Communications and Strategy
(469) 374-8721
ir@reatapharma.com
http://reatapharma.com/contact-us/
FAQ
When will Reata Pharmaceuticals report its Q2 2020 financial results?
What time is the Reata Pharmaceuticals conference call?
What are the main drug candidates of Reata Pharmaceuticals?
Are bardoxolone and omaveloxolone approved drugs?
